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Purpose: Disorders or differences of sex development (DSDs) are
rare congenital conditions characterized by atypical sex develop-
ment. Despite advances in genomic technologies, the molecular
cause remains unknown in 50% of cases.
Methods: Homozygosity mapping and whole-exome sequencing
revealed an ESR2 variant in an individual with syndromic 46,XY
DSD. Additional cases with 46,XY DSD underwent whole-exome
sequencing and targeted next-generation sequencing of ESR2.
Functional characterization of the identified variants included
luciferase assays and protein structure analysis. Gonadal ESR2
expression was assessed in human embryonic data sets and
immunostaining of estrogen receptor-β (ER-β) was performed in
an 8-week-old human male embryo.
Results:We identified a homozygous ESR2 variant, c.541_543del p.
(Asn181del), located in the highly conserved DNA-binding domain
of ER-β, in an individual with syndromic 46,XY DSD. Two
additional heterozygous missense variants, c.251G>T p.(Gly84Val)
and c.1277T>G p.(Leu426Arg), located in the N-terminus and the
ligand-binding domain of ER-β, were found in unrelated, nonsyn-
dromic 46,XY DSD cases. Significantly increased transcriptional
activation and an impact on protein conformation were shown for
the p.(Asn181del) and p.(Leu426Arg) variants. Testicular ESR2
expression was previously documented and ER-β immunostaining
was positive in the developing intestine and eyes.
Conclusion: Our study supports a role for ESR2 as a novel
candidate gene for 46,XY DSD.
Genet Med advance online publication 26 October 2018
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INTRODUCTION
In humans, gonadal fate is determined by the presence or
absence of sex-specific gene expression. In the bipotential
stage of development, transcription factors such as Wilms’
tumor 1, nuclear receptor subfamily 5 group A member 1
(NR5A1) and GATA-binding protein 4 (GATA4) lead to
upregulation of the sex-determining region Y gene (SRY) in
the male embryo, thereby initiating the male developmental
signaling cascade, with the expression of other male-specific
genes such as SRY-box 9 (SOX9).1 In addition, several reports
indicate an important role for the mitogen-activated protein
kinase (MAPK) pathway in the early phases of (male) sex
determination.2–4 In female embryos lacking the Y chromo-
some, female-specific genes like R-spondin 1 and forkhead box
L2 (FOXL2) are expressed among others.1,5 Animal studies
have revealed multiple and long-lasting interactions between
these male and female pathways; for instance, the loss of Foxl2
or Dmrt1 in murine adult granulosa and Sertoli cells,
respectively, results in trans-differentiation to an opposite cell
fate.6,7
Subtle imbalances of this strictly regulated sex-specific gene
network can lead to disorders or differences of sex develop-
ment (DSD).1 Currently, mutations in genes known to be
involved in sex development explain the molecular pathogen-
esis in only a minority of 46,XY DSD cases.1,7 Next-
generation-sequencing-based approaches such as whole-
exome sequencing improve the identification of causal genetic
defects, and the discovery of new genes and signaling
pathways implicated in sex development.8,9 Elucidating the
underlying causes of DSD can facilitate sex assignment and
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lead to improved management, a better prognosis and a more
accurate evaluation of gonadal function and gonadal germ cell
cancer risk.10
So far, mutations in genes encoding nuclear receptors, such
as NR5A1 (also known as the steroidogenic factor 1 gene, or
SF1)11 and the androgen receptor NR3C4 gene12 have been
implicated in DSD pathogenesis as well as the duplication of
the nuclear receptor subfamily 0 group B member 1 gene
(NR0B1, DAX1).13 Here, we identified biallelic and mono-
allelic estrogen receptor 2 (ESR2) variants in one syndromic
and two nonsyndromic 46,XY DSD cases, respectively,
putting forward ESR2 as a novel disease gene for 46,XY
DSD and expanding the spectrum of nuclear receptors
implicated in 46,XY DSD etiology.
MATERIALS AND METHODS
Study subjects
Laboratory and clinical investigations of cases 1–3 are
summarized in Table 1. Cases and/or parents provided
written informed consent for the study. Detailed case reports
can be found in Supplementary Data S1–S3 online.
Genetic studies
Homozygosity mapping was performed by genome-wide
single-nucleotide polymorphism (SNP) genotyping in case 1
and in two unaffected siblings using the HumanCytoSNP-12
BeadChip platform (Illumina, San Diego, CA). Plink software,
integrated in ViVar, identified homozygous regions of
> 1Mb, which were ranked according to their length and
the number of SNPs, as described.14 Only homozygous
regions unique to the index case were selected. The presence
of relevant known DSD genes was excluded using BioMart
filtering. Next, different gene prioritization tools (Endeavour,
GeneDistiller, GeneWanderer, PosMed, SUSPECTS, and
ToppGene) were used to identify candidate genes in the
selected regions.15 For this purpose, known DSD genes were
used as training genes (Supplementary Data and
Supplementary Table S1 online).
Sanger sequencing and targeted next-generation
sequencing
Primers were developed for polymerase chain reaction
amplification and sequencing of all coding exons, intron–
exon boundaries and untranslated regions of ESR2
(Supplementary Data and Supplementary Table S2
online). Sanger sequencing (cases 1 and 2) was performed
using an ABI 3730XL DNA Analyzer (Applied Biosystems,
Carlsbad, CA) with the BigDye Terminator v3.1 Cycle
Sequencing Kit (Applied Biosystems) followed by data
analysis with SeqScape Software v2.5 (Life Technologies,
Europe, Ghent, Belgium). Targeted next-generation sequen-
cing of 63 DSD disease and candidate genes including ESR2
was performed (case 3) with a MiSeq System instrument.
Details of the target enrichment, variant annotation and
filtering can be found in Supplementary Data S4 online.
Segregation analysis for the ESR2 variant found in case 1
was performed in the available family members. Apart from
the mother, no family members were available for further
analysis in case 2. For case 3, no parental DNA was available
for segregation analysis. Variant classification was performed
following the American College of Medical Genetics and
Genomics (ACMG) guidelines of 2015.16
Whole-exome sequencing was performed to exclude the
presence of other likely pathogenic variants. Exome enrich-
ment was performed with the Nextera Rapid Capture Exome
kit (Illumina), followed by paired-end sequencing on HiSeq
2000 (2 × 100 cycles) (Illumina). Reads were mapped against
the human reference genome sequence (National Center for
Biotechnology Information, GRCh37/hg19) with the CLC
Genomics Workbench v6.4 (Qiagen, Venlo, The Netherlands)
followed by postmapping duplicate read removal, coverage
analysis, and quality-based variant calling. More thorough
variant annotation was executed using Alamut-HT v1.1.5
software (Interactive Biosoftware, Rouen, France) and a
complementary literature search after extensive screening
(Supplementary Table S3–S5 online).
Targeted NR5A1 testing
In cases 1 and 2, targeted next-generation sequencing of the
coding region of NR5A1 was performed using a previously
described workflow,17 and copy-number variant analysis
was performed using multiplex ligation-dependent probe
amplification (SALSA MLPA P185 Intersex probemix; MRC-
Holland, Amsterdam, The Netherlands). In case 3 NR5A1
sequence variants and copy-number variants were excluded
by the aforementioned targeted next-generation sequencing
panel analysis.
Structural analysis of the estrogen receptor-β (ER-β)
variants
Models for the wild-type ER-β DNA-binding domain
(DBD) were built using the standard homology modeling
procedure in YASARA Structure (http://yasara.org/products).
We used the structure of the ER-β bound to a DNA response
element (pdb code 1HCQ) as a template.18 We built
models for dimers of the wild-type DBD with and without
DNA. A model for the p.(Asn181del) (N181del) mutation
(found in case 1) was built in YASARA Structure based
on the wild-type model, by deleting residue N181 and
introducing a new peptide bond between residues 180 and
182, followed by energy minimization (the em_runclean
protocol in YASARA Structure). The homodimer models for
the wild-type and N181del mutant DBDs were further
subjected to 500 ps of molecular dynamics with the YASARA2
forcefield, followed by energy minimization using the
md_refine procedure.19
Using FoldX and the estrogen-bound ER-β ligand-binding
domain (LBD) structure with pdb code 3OLL, we calculated
an in silico estimate of the Gibbs energy of protein folding for
the mutant and wild-type LBD using the RepairPDB and
BuildModel commands.20,21 For each mutant, we report the
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average ΔΔG for the folding of mutant versus wild-type of 20
BuildModel calculations. The 3OLL protein structure was
visualized in UCSF Chimera.22 The effect of the p.
(Leu426Arg) (L426R) mutation (found in case 3) was
visualized by replacing L426 with the best-fitting arginine
rotamer in the Dunbrack backbone-dependent rotamer
library.
ESR2 expression analysis in human embryonic tissue
Assessment of human embryonic expression data sets
ESR2 expression in the testis was assessed in RNA sequencing
data generated by Gerrard et al.23 in human embryos of
Carnegie stages 18 and 22 and in array expression data
generated by del Valle et al.24 in embryonic gonadal and
adrenal tissues.
Immunohistochemistry
Tissue slides (4 μm) were prepared from a formalin-fixed,
paraffin-embedded 8-week-old male fetus obtained after
spontaneous abortion. Before immunohistochemistry, a
heat-induced antigen retrieval step (Tris-EGTA, pH 9.00)
was included. We used a standard ABC protocol for the
detection of ER-β. After blocking endogenous peroxidase and
biotin (Avidin/Biotin Blocking Kit SP-2001) and overnight
incubation with mouse anti-ER-β (dilution 1/50; Dako
M7292), detection was performed with a biotinylated rabbit
antimouse antibody (dilution 1/150, 30 min; Dako E413)
followed by 30 min of incubation with Avidin–Biotin–HRP-
labeled complex (VECTASTAIN Elite ABC HRP Kit PK-
-6100). Visualization was done with DAB/H2O2 and hema-
toxylin counterstaining.
Luciferase assays
Plasmid construction
Plasmids containing the ESR2 variants were constructed with
site-directed mutagenesis starting from a pcDNA–flag–ER-β
plasmid (35562; Addgene, Cambridge, MA). Mutagenesis
primers were designed using the NEBaseChanger software
(http://nebasechanger.neb.com/). After amplification, the
plasmids were digested with DpnI to remove nonmutated
DNA. After verifying that mutations had correctly been
inserted via sequence analysis, mutated plasmids were
transformed in chemically competent Escherichia coli
(DH10b cells) and subsequently isolated with the NucleoBond
Xtra Midi/Maxi kit (Macherey-Nagel, Düren, Germany).
Cell culture and luciferase assays
HEK293T cells were cultured in Dulbecco’s minimal essential
medium without phenol red, supplemented with 10%
charcoal-stripped fetal bovine serum (Life Technologies,
Europe, Ghent, Belgium) and 10 μg/ml gentamycin
at 37 °C and 8% CO2. A total of 300,000 cells per well
were plated in 6-well plates. Cells were transfected with a total
of 2 μg of DNA using a standard calcium phosphate
transfection method. After 24 h, cells were washed with
phosphate buffered saline and subsequently stimulated withTa
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2,3-bis(4-hydroxyphenyl)propionitrile (DPN) to a final con-
centration of 10 nM. Following lysis with 1 × cell culture lysis
reagent (25 mM Tris-phosphate pH 7.8, 2 mM dithiothreitol,
2 mM 1,2-cyclohexylenedinitrilotetraacetic acid, 10% glycerol,
and 1% Triton X-100), luciferase activity was measured 24 h
after stimulation on a TopCount luminometer (Canberra–
Packard, Meriden, CT). To normalize for differences in
transfection efficiency, a plasmid constitutively expressing β-
galactosidase was cotransfected in all experiments (Tropix
Galacto-Star system; Applied Biosystems, Foster City, CA).
Each transfection was replicated in at least three independent
experiments. Differences in expression between wild-type and
mutated ER-β were demonstrated for variants 1 and 2 using a
control western blot (data not shown).
RESULTS
Identification of a homozygous ESR2 variant in case 1 with
syndromic 46,XY DSD
Given the possible parental consanguinity, we performed
homozygosity mapping to identify runs of homozygosity
containing the putative underlying genetic cause of the
syndromic 46,XY DSD phenotype in case 1. Twenty-one
homozygous regions larger than 1Mb were identified
(Supplementary Data and Supplementary Table S6
online). The largest one—with a length of 20 Mb—is located
on chromosome 14 and contains 465 genes, none of which are
known DSD genes. The gene encoding 5α-reductase, SRD5A2,
was present in another small homozygous region (3.6 Mb);
however, no potentially pathogenic variants were found in its
coding region. Variant prioritization ranked ESR2 as the top
candidate gene (Supplementary Data and Supplementary
Table S7 online). Sequencing of ESR2 revealed a homozygous
3-bp deletion in exon 9, c.541_543del, leading to an in-frame
deletion, p.(Asn181del) (Figure 1a,b). This deletion affects a
highly conserved amino acid located in the DBD (Figure 1a,
b). The deletion was found to be absent in 92 tested ethnically
matched control chromosomes and 320 other tested control
chromosomes. This variant is reported at very low frequencies
in publicly available databases (the Exome Sequencing
Project, the Exome Aggregation Consortium 0.3.1, and
gnomAD); however, no homozygotes have previously been
identified (variant details in Supplementary Data and
Supplementary Table S8 online). Segregation analysis
showed that both parents (Figure 1b; I:1 and I:2) and one
healthy 46,XX sibling (Figure 1b; II:2) are heterozygous
carriers of the deletion, while another 46,XX sibling
(Figure 1b; II:3) is homozygous for the wild-type allele.
Variant classification following the ACMG guidelines cate-
gorizes p.(Asn181del) as likely pathogenic (class 4) (Table 2).
Whole-exome sequencing in the index case and the parents
made the presence of other potentially pathogenic coding
variants very unlikely. An overview of the variant filtering,
performed as previously described,14 is given in
Supplementary Tables S3 and S4 online.
Identification of two heterozygous ESR2 missense variants
in case 2 and 3 with nonsyndromic 46,XY DSD
Targeted resequencing of the ESR2 coding region in a Belgian
46,XY DSD cohort (n = 73) and a Brazilian 46,XY DSD
cohort (n = 40) revealed two heterozygous missense variants
in two unrelated cases with nonsyndromic 46,XY DSD. In
case 2, a heterozygous ESR2 variant c.251G>T was found in
exon 2, leading to a missense change p.(Gly84Val) affecting a
highly conserved amino acid (up to fruit fly) located in the
N-terminal domain, which contains the first activation
function of the receptor (Figure 1a). The physicochemical
difference between Gly and Val is moderate (a Grantham
distance of 109). Several prediction programs (SIFT,
PolyPhen-2, and MutationTaster) suggest a deleterious
effect on protein function. The variant is absent in 412
tested control chromosomes and in genomic databases such
as dbSNP, the Exome Sequencing Project, and the Exome
Aggregation Consortium. In gnomAD, it occurs in 0.000396%
(no homozygotes) (Table 2). Following the ACMG guidelines,
p.(Gly84Val) could be scored as likely pathogenic (class 4)
(Table 2). Whole-exome sequencing did not reveal any other
potentially pathogenic variants in case 2. An overview of the
different filtering steps and variants is given in
Supplementary Tables S3 and S5 online. In case 3, a
heterozygous variant—c.1277T>G in exon 8 of ESR2—was
found, leading to the missense change p.(Leu426Arg) in the
LBD and affecting a highly conserved amino acid (up to
Tetraodon). The Grantham distance between Leu and Arg is
moderate (i.e., 102) and several prediction programs
show a potential deleterious effect. This variant is not
present in the consulted genomic databases (dbSNP, the
Exome Sequencing Project, the Exome Aggregation
Consortium, and gnomAD), nor in 214 Brazilian exomes
(Table 2). Following the ACMG guidelines, p.(Gly84Val)
could be classified as a variant of unknown significance (class
3) (Table 2). Whole-exome sequencing did not reveal any
other potentially pathogenic variants in case 3. Figure 1 and
Table 2 summarize the location and characteristics of the
identified ESR2 variants.
Structural analysis of the ER-β variants
The ER-β DBD binds to DNA as a homodimer. We built
homology models for the wild-type and p.(Asn181del) mutant
homodimer. Residue Asn181 is part of a longer extended loop
that connects the main DNA-binding helix to a zinc
coordination site, which is part of the homodimer interface.
The Asn181 deletion shortens this connecting loop and causes
a 15° tilt of the main DNA-binding helix (Figure 2a,b).
Molecular dynamics simulation, followed by energy
minimization, suggests that this slightly affects the orientation
between the two DBDs in the homodimer, with an increased
number of contacts between the two domains (Figure 2a,b). It
is therefore very likely that the Asn181 deletion affects
homodimerization and/or DNA binding of the ER-β.
There was no template available for remodeling of the p.
(Gly84Val) variant, and no homology models could be
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obtained. To assess the possible influence of the p.
(Leu426Arg) missense variant on the ER-β protein structure,
we made in silico calculations of ΔΔG with FoldX and tried to
model the best rotamer position for each variant with UCSF
Chimera. The p.(Leu426Arg) variant is located in the LBD,
which was previously characterized by X-ray crystallography.
Leu426 is a buried residue of helix 9 (Figure 2a). FoldX
energy calculations using the BuildModel command indicate
that the p.(Leu426Arg) mutation affects the folding energy
of the protein and has a destabilizing effect (in silico
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ΔΔG = 2.3 kcal/mol). Leu426 fits in a hydrophobic pocket
and engages in interactions with Leu322, Leu330, Leu406, and
Met410 (Figure 2b). Modeling the best-fitting Arg rotamer at
the position of Leu426 in UCSF Chimera shows that this
mutation abolishes most of these hydrophobic interactions,
while even the best-fitting rotamer of the Arg side chain
introduces strong steric clashes in the absence of drastic
energy minimization (green lines) (Figure 2c). The p.
(Leu426Arg) variant is likely to affect the stability or folding
of the LBD domain. Folding of the p.(Leu426Arg) variant
estrogen-bound LBD domain into a wild type-like structure
would at least require drastic structural changes in the
environment of residue 426, which could hamper LBD
dimerization, as helix 9 and the loop between helix 8 and 9
(which interacts with Leu426 via Met410) are both part of the
symmetrical LBD dimer interface.
Expression studies in human embryos
In RNA sequencing data generated by Gerrard et al.23 in
embryos of Carnegie stages 18 and 22 (7 and 8 weeks; i.e.,
around the time of sex determination), ESR2 expression could
be observed in testicular tissues. In array expression data
generated by del Valle et al.24 in a genomic atlas of human
adrenal and gonadal development, early expression of ESR2
could be confirmed. In a human male embryo with a
gestational age of 8 weeks, ER-β immunostaining was positive
in the developing eye, especially in the corneal epithelium and
endothelium, primitive lens neurons, primitive retinal cells
and retinal pigment epithelium, mucosa of the developing
intestine, and neuronal system (specifically the primitive
neurons of the germinal matrix). ER-β staining was negative
in the developing testis at this stage of development
(Supplementary Data and Supplementary Figure S1 online).
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Figure 2 Structural analysis of mutated and wild-type ER-β. (a) Effect of the Asn181 deletion on a dimer of the ER-β DNA-binding domain. A
model for a dimer of both the wild-type (blue) and Asn181del mutant (red) DNA-binding domain is shown. Monomer 1 of both dimers is superposed.
The Asn181 (N181) deletion shortens a long loop between the DNA-binding helix and the zinc-binding site at the dimer interface. As a result, the
DNA-binding helix tilts towards the dimer interface. The red arrow indicates an upward shift of the second monomer versus the first monomer in the
mutant dimer. The molecules are rotated 90° compared with (b) and the DNA-binding helices are directed towards the viewer. (b) Model of the wild-
type ER-β DNA-binding domain bound to DNA. The position of Asn181 is indicated. (c) Position of the Leu270 (L270) and Leu426 (L426) residues in
the ER-β ligand-binding domain structure. Atoms of L270 and L426 are shown as gray spheres. (d) L426 is buried in a hydrophobic environment in the
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D326 and M410 (red lines).
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Transcriptional activation assays
The impact of the identified variants on transcriptional
activation was assessed using luciferase assays with
TK-3xERE-promoter constructs. The p.(Asn181del) variant
resulted in significantly increased transcriptional activation after
stimulation with the ER-β-specific ligand, DPN (Po 0.001).
For the two missense variants, p.(Gly84Val) and p.(Leu426Arg),
no significant alterations of ligand-dependent transcriptional
activation were observed (Figure 3). Interestingly, the p.
(Leu426Arg) variant shows a higher transcriptional activation
compared with wild-type ER-β when the cells are not
stimulated with DPN (P = 0.0014).
DISCUSSION
The identification of likely pathogenic variants in ESR2 in
unrelated individuals with 46,XY gonadal dysgenesis suggests
an unanticipated role for ER-β in early gonadal development.
Previously, polymorphic ESR2 variants have been associated
with milder variations in sexual development such as
hypospadias and micropenis,25–29 and a heterozygous ESR2
variant c.1295C>A leading to a missense change p.
(Ala432Asp) in the LBD of ER-β was recently reported in a
girl with primary amenorrhea.30
Here, we identified a biallelic in-frame deletion in a girl with
syndromic 46,XY DSD and two monoallelic missense variants
in two unrelated cases with nonsyndromic 46,XY DSD. The
data of case 1 are suggestive of absent gonadal development,
while the data of cases 2 and 3 are compatible with partial and
complete gonadal dysgenesis. A combination of different
parameters including population frequencies and in silico
predictions support a likely pathogenic classification for two
of the three variants found (Table 2). Structural analyses
support a deleterious effect of the p.(Asn181del) and p.
(Leu426Arg) variants on protein conformation, but are not
available for the p.(Gly84Val) variant due to the absence of a
suitable model for this region. A significant increase in
transcriptional activation was shown for the p.(Asn181del)
and p.(Leu426Arg) variants and resulted in increased activity
in the absence of an ER-β-specific ligand.
In recently published human embryonic gonadal expression
databases, ESR2 expression was found in early stages of
gonadal development. In an 8-week-old male human embryo,
ER-β immunostaining was shown in the developing intestine,
eye, and neuronal systems, potentially reflecting the extra-
gonadal involvement in case 1. However, no testicular
immunostaining was observed at this developmental time
point. Given the severity of the observed gonadal phenotypes,
it cannot be excluded that ER-β plays a role even earlier
during development.
An interesting finding in this respect is the fact that
nonclassical estrogen signaling has been shown previously to
interact with the MAPK pathway31—a signaling pathway
involved in the earliest stages of gonadal development—
although the operating mechanisms are different in humans
and mice. In humans, MAPK signaling is essential for tilting
the gene expression balance towards SOX9 expression; gain-
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Figure 3 Transcriptional activation assays. Results are shown as the mean ± SEM for relative luciferase intensity units (R.L.U.). The analysis involved
the fitting of a hierarchical generalized linear model to the R.L.U. data, as implemented in Genstat v18, with transfection and stimulation as fixed terms
(Poisson distribution; log link) and replicates (n = 4 or higher) nested within experimenter as additional random terms (gamma distribution; log link).
**Po 0.01. The difference between WT and Asn181del is significant at the 0.001 level. For variants 1 and 2, the experiment was repeated 11 times
respectively with three to six technical replicates each time; for variant 3, the experiment was repeated seven times with six replicates each time.
DMSO, dimethylsulfoxide; DPN, 2,3-bis(4-hydroxyphenyl)propionitrile.
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of-function mutations of MAP3K1 lead to higher phosphor-
ylation of downstream targets, causing decreased expression
of SOX9 and increased expression of female-specific genes like
β-catenin.2,31,32 In mice, the Mapk pathway acts through
direct upregulation of Sry; homozygous loss-of-function
variants of Map3k4 are reflected in a male-to-female sex
reversal phenotype.3,33
Nuclear receptor family members, to which the ERs belong,
are known to exert their functions through different action
mechanisms. The classical genomic pathway involves ligand
binding and receptor dimerization, followed by nuclear
translocation and activation or repression of target gene
expression.34,35 Estrogen binds on both ER-α and ER-β
receptors; however, binding results in partially overlapping
but also differential transcriptional effects.36,37 Alternative
action mechanisms involve interactions with other transcrip-
tion factors, ligand-independent receptor activation, and
activation of different signaling pathways. For instance, it
has been shown that ER-β can activate specific MAPK
pathways in human colon cancer cell lines. The scarce
experimental data regarding these alternative pathways
indicate that these processes are highly cell specific, making
it hard to investigate them in a development gonadal context
as the currently available cell lines do not mimic the
embryonic cellular environment. We hypothesize that the
ESR2 variants found here could lead to increased activation of
the MAPK pathway via a nongenomic working mechanism,
thereby shifting the expression balance from SOX9 to β-
catenin signaling, and resulting in decreased SOX9 activation
and failure of testicular development (Supplementary Data
and Supplementary Figure S2 online). Experimental
validation of this hypothesis is challenging given the cell-
type specificity of these alternative pathways and the fact that
no relevant cell line resembling the undifferentiated gonad is
available. Furthermore, it remains complex to acquire an
experimental setup that resembles the earliest phases of sex
development as all available gonadal cell lines are
differentiated.
A differential action mode of MAPK signaling in mice and
humans can explain the absence of a sex reversal phenotype in
ER-β knockout mouse models. Over the years, several ER-β
KO mice have been generated. A first mouse knockout model
was characterized by female sub- or infertility and normal
reproductive capacity in males.38 This mouse was generated
through insertion of a neomycin resistance gene into exon 3
of the Esr2 gene by homologous recombination in embryonic
stem cells. Several transcripts were still being processed,
however, leading to an incomplete knockout. Moreover, ER-β
knockout mice originating from the same initial ER-β mutant
but raised and examined in different laboratories presented
with a range of different phenotypes. A new ER-β knockout
mouse used Cre/LoxP-mediated excision of the third exon of
Esr2, resulting in complete absence of any Esr2 transcript.
These mice show infertility in both sexes, but no sex reversal.
A similar situation has been reported for another nuclear
receptor, NR0B1 (DAX1), for which duplications lead to male-
to-female sex reversal in humans, but delayed testis develop-
ment in mice.39
Differences in zygosity have been shown for the ESR2
variants found here, and may relate to the nonsyndromic
phenotype in the two monoallelic cases compared with the
syndromic phenotype in the biallelic case. Moreover, a
different working mechanism cannot be excluded for the
monoallelic missense variants found, although they may all
act via the same dysregulated MAPK pathway. Differences in
zygosity and mutation-dependent action mechanisms have
been described for other nuclear receptors, such as NR2E3,
implicated in both autosomal dominant and recessive retinal
dystrophies with clinically distinct phenotypes.40
CONCLUSION
We identified biallellic and monoallelic variants in ESR2 in
patients with syndromic and nonsyndromic 46,XY DSD,
respectively, putting forward ESR2 as a novel candidate gene
for 46,XY DSD etiology. It is interesting to speculate about an
unanticipated role for ER-β in early gonadal development; i.e.,
the development and stabilization of the bipotential gonad
and/or its differentiation into a functional testis.
SUPPLEMENTARY MATERIAL
Supplementary material is linked to the online version of the
paper at http://www.nature.com/gim
ACKNOWLEDGMENTS
This work was supported by grants from the Research Foundation
—Flanders (FWO) (Bilateral Scientific Cooperation Brazil NXT-
DSDG0D6713N to E.D.B. and M.C.), the Ghent University Special
Research Fund (BOF15/GOA/011 to E.D.B. and a BOF Starting
Grant to M.C.), and Belspo IAP project P7/43 (Belgian Medical
Genomics Initiative to E.D.B). E.D.B. and M.C. are senior clinical
investigators of the Research Foundation—Flanders. H.V. is a
postdoctoral fellow of the Research Foundation—Flanders. We
are most grateful to the family members who participated in
this study.
ESR2 STUDY GROUP
Zeynep Atay (Pediatric Endocrinology and Diabetes, Marmara
University, Turkey); Abdullah Bereket (Pediatric Endocrinology and
Diabetes, Marmara University, Turkey); Ronald R de Krijger
(Reinier de Graaf Hospital, Delft, The Netherlands); Katleen de
Preter (Center for Medical Genetics, Ghent University and Ghent
University Hospital, Belgium); Sorahia Domenice (Disciplina de
Endocrinologia, Laboratorio de Hormonios e Genetica Molecular
LIM/42, Unidade de Adrenal, Disciplina de Endocrinologia e
Metabologia, Hospital das Clínicas, Faculdade de Medicina da
Universidade de São Paulo, São Paulo, Brazil); Serap Turan
(Pediatric Endocrinology and Diabetes, Marmara University,
Turkey).
DISCLOSURE
The authors declare no conflict of interest.
ORIGINAL RESEARCH ARTICLE BAETENS et al | ESR2 variants associated with 46,XY DSD
726 Volume 20 | Number 7 | July 2018 | GENETICS in MEDICINE
REFERENCES
1. Ono M, Harley VR. Disorders of sex development: new genes, new
concepts. Nat Rev Endocrinol 2013;9:79–91.
2. Pearlman A, Loke J, Le Caignec C, et al. Mutations in MAP3K1 cause 46,
XY disorders of sex development and implicate a common signal
transduction pathway in human testis determination. Am J Hum Genet
2010;87:898–904.
3. Bogani D, Siggers P, Brixey R, et al. Loss of mitogen-activated protein
kinase kinase kinase 4 (MAP3K4) reveals a requirement for MAPK
signalling in mouse sex determination. PLoS Biol 2009;7:e1000196.
4. Warr N, Bogani D, Siggers P, et al. Minor abnormalities of testis
development in mice lacking the gene encoding the MAPK signalling
component, MAP3K1. PLoS ONE 2011;6:e19572.
5. Uhlenhaut NH, Jakob S, Anlag K, et al. Somatic sex reprogramming of
adult ovaries to testes by FOXL2 ablation. Cell 2009;139:1130–1142.
6. Matson CK, Murphy MW, Sarver AL, Griswold MD, Bardwell VJ,
Zarkower D. DMRT1 prevents female reprogramming in the postnatal
mammalian testis. Nature 2011;9:1–5.
7. Hughes IA, Houk C, Ahmed SF, Lee PA. Consensus statement on
management of intersex disorders. Arch Dis Child 2006:554–563.
8. Bashamboo A, Ledig S, Wieacker P, Achermann J, McElreavey K. New
technologies for the identification of novel genetic markers of disorders
of sex development (DSD). Sex Dev 2010;15:213–224.
9. Baxter RM, Arboleda VA, Lee H, et al. Exome sequencing for the
diagnosis of 46, XY disorders of sex development. J Clin Endocrinol
Metab 2015;100:E333–E344.
10. Cools M, Wolffenbuttel KP, Drop SLS, Oosterhuis JW, Looijenga LHJ.
Gonadal development and tumor formation at the crossroads of male
and female sex determination. Sex Dev 2011;5:167–180.
11. Ferraz-de-Souza B, Lin L, Achermann JC. Steroidogenic factor-1 (SF-1,
NR5A1) and human disease. Mol Cell Endocrinol 2011;336:198–205.
12. Mongan N, Tadokoro-Cuccaro R, Bunch T, Hughes I. Androgen insensitivity
syndrome. Best Pract Res Clin Endocrinol Metab 2015;29:569–580.
13. Orekhova AS, Rubtsov PM. DAX1, an unusual member of the nuclear
receptor superfamily with diverse functions. Mol Biol 2015;49:65–76.
14. Coppieters F, Van Schil K, Bauwens M, et al. Identity-by-descent-guided
mutation analysis and exome sequencing in consanguineous families
reveals unusual clinical and molecular findings in retinal dystrophy. Genet
Med 2014;16:671–680.
15. Tranchevent L-C, Capdevila FB, Nitsch D, De Moor B, De Causmaecker P,
Moreau Y. A guide to web tools to prioritize candidate genes. Brief
Bioinform 2011;12:22–32.
16. De Leeneer K, Hellemans J, Steyaert W, et al. Flexible, scalable, and
efficient targeted resequencing on a benchtop sequencer for variant
detection in clinical practice. Hum Mutat 2015;36:379–387.
17. Richards S, Aziz N, Bale S, et al. Standards and guidelines for the
interpretation of sequence variants: a joint consensus recommendation
of the American College of Medical Genetics and Genomics and the
Association for Molecular Pathology. Genet Med 2015;17:405–424.
18. Schwabe JWR, Chapman L, Finch JT, Rhodes D. The crystal structure of the
estrogen receptor DNA-binding domain bound to DNA: how receptors
discriminate between their response elements. Cell 1993;75:567–578.
19. Krieger E, Joo K, Lee J, et al. Improving physical realism, stereochemistry,
and side-chain accuracy in homology modeling: four approaches that
performed well in CASP8. Proteins 2009;77:114–122.
20. Guerois R, Nielsen JE, Serrano L. Predicting changes in the stability of
proteins and protein complexes: a study of more than 1000 mutations. J
Mol Biol 2002;320:369–387.
21. Möcklinghoff S, Rose R, Carraz M, Visser A, Ottmann C, Brunsveld L.
Synthesis and crystal structure of a phosphorylated estrogen receptor
ligand binding domain. Chembiochem 2010;11:2251–2254.
22. Pettersen EF, Goddard TD, Huang CC, et al. UCSF Chimera—a
visualization system for exploratory research and analysis. J Comput
Chem 2004;25:1605–1612.
23. Gerrard DT, Berry AA, Jennings RE, Hanley KP, Bobola N, Hanley NA. An
integrative transcriptomic atlas of organogenesis in human embryos.
eLlife 2016;5:1–16.
24. Del Valle I, Buonocore F, Duncan AJ, et al. A genomic atlas
of human adrenal and gonad development. Wellcome Open Res
2017;2:25.
25. Ban S, Sata F, Kurahashi N, et al. Genetic polymorphisms of ESR1 and
ESR2 that may influence estrogen activity and the risk of hypospadias.
Hum Reprod 2008;23:1466–1471.
26. Beleza-Meireles A, Omrani D, Kockum I, Frisén L, Lagerstedt K,
Nordenskjöld A. Polymorphisms of estrogen receptor β gene are
associated with hypospadias. J Endocrinol Invest 2006;29:5–10.
27. Beleza-Meireles A, Kockum I, Lundberg F, Söderhäll C, Nordenskjöld A.
Risk factors for hypospadias in the estrogen receptor 2 gene. J Clin
Endocrinol Metab 2007;92:3712–3718.
28. Van der Zanden LFM, van Rooij I A LM, Feitz WFJ, Franke B, Knoers NV A
M, Roeleveld N. Aetiology of hypospadias: a systematic review of genes
and environment. Hum Reprod Update 2012;18:260–283.
29. Van der Zanden LF, van Rooij IA, Feitz WF, Franke B, Knoers NV,
Roeleveld N. Genetics of hypospadias: are single-nucleotide
polymorphisms in SRD5A2, ESR1, ESR2, and ATF3 really asso-
ciated with the malformation? J Clin Endocrinol Metab 2010;95:
2384–2390.
30. Asadi M, Ghafouri-Fard S, Zare-Abdollahi D, Ebrahim-Habibi A, Matin N.
Estrogen receptor mutation in a girl with primary amenorrhea. Clin Genet
2013;83:497–498.
31. Drummond AE, Fuller PJ. The importance of ERbeta signalling in
the ovary. J Endocrinol 2010;205:15–23.
32. Marino M, Galluzzo P, Ascenzi P. Estrogen signaling multiple pathways
to impact gene transcription. Curr Genomics 2006;7:497–508.
33. Loke J, Pearlman A, Radi O, et al. Mutations in MAP3K1 tilt the balance
from SOX9/FGF9 to WNT/β-catenin signaling. Hum Mol Genet 2014;23:
1073–1083.
34. Ostrer H. Disorders of sex development (DSDs): an update. J Clin
Endocrinol Metab 2014;99:1503–1509.
35. Pettersson K, Gustafsson JA. Role of estrogen receptor beta in
estrogen action. Annu Rev Physiol 2001;64:65–92.
36. Segars JH, Driggers PH. Estrogen action and cytoplasmic signaling
cascades. Part I: membrane-associated signaling complexes. Trends
Endocrinol Metab 2002;13:349–354.
37. Driggers PH, Segars JH. Estrogen action and cytoplasmic signaling
pathways. Part II: the role of growth factors and phosphorylation in
estrogen signaling. Trends Endocrinol Metab 2002;13:422–427.
38. Krege JH, Hodgin JB, Couse JF, et al. Generation and reproductive
phenotypes of mice lacking estrogen receptor beta. Proc Natl Acad Sci
USA 1998;95:15677–15682.
39. Swain A, Narvaez V, Burgoyne P, Camerino G, Lovell-badge R. Dax1
antagonizes Sry action in mammalian sex determination. Nature
1998;391:761–767.
40. Coppieters F, Leroy BP, Beysen D, et al. Recurrent mutation
in the first zinc finger of the orphan nuclear receptor NR2E3 causes
autosomal dominant retinitis pigmentosa. Am J Hum Genet 2007;81:
147–157.
Thiswork is licensedunder a CreativeCommons
Attribution-NonCommercial-NoDerivs 4.0
International License. The images or other third party
material in this article are included in the article’s Creative
Commons license, unless indicated otherwise in the credit
line; if the material is not included under the Creative
Commons license,userswill need toobtainpermission from
the license holder to reproduce thematerial. To viewa copy
of this license, visit http://creativecommons.org/licenses/
by-nc-nd/4.0/
© The Author(s) 2018
ESR2 variants associated with 46,XY DSD | BAETENS et al ORIGINAL RESEARCH ARTICLE
GENETICS in MEDICINE | Volume 20 | Number 7 | July 2018 727
